Recent news highlights MapLight's FY25 financial results, clinical trial progress, FDA Fast Track designation, insider buying activity, and analyst coverage initiation.

• MapLight reported FY25 results and announced multiple Phase 2 readouts anticipated in 2026 [N1].
• Canaccord Genuity initiated coverage of MapLight Therapeutics with a buy recommendation [N2].
• Insider buying activity was reported in February 2026, indicating insider confidence [N3].
• The company updated the expected timing of topline results for ongoing Phase 2 studies to Q3 2026 [N4].
• ML-007C-MA received FDA Fast Track designation for Alzheimer's disease psychosis treatment [N5].
• MapLight plans to report schizophrenia trial results in the second half of 2026 [N6].

MapLight's lead candidate ML-007C-MA has advanced through multiple Phase 1 trials and is in Phase 2 studies targeting schizophrenia and Alzheimer's disease psychosis, with FDA Fast Track designation for ADP. The company has a strong cash position following its IPO and private placement, supporting ongoing clinical development. Its novel approach targeting neural circuits may offer differentiated efficacy and safety profiles. Positive clinical trial readouts could validate its platform and open pathways for commercialization and partnerships.

MapLight has incurred significant net losses and an accumulated deficit, reflecting the high costs and risks of clinical-stage biopharmaceutical development. The company has no current product revenue and depends on capital markets and partnerships for funding. Clinical trials carry inherent risks including enrollment challenges, regulatory hurdles, and potential failure to demonstrate safety or efficacy. Operational risks include cybersecurity threats and the need to scale infrastructure. Failure to secure additional funding or achieve regulatory approvals could materially impact the company's viability.

MapLight Therapeutics' moat is based on its proprietary discovery platform targeting neural circuits causally linked to CNS disorders, and its lead candidate ML-007C-MA, which combines targeted muscarinic receptor activation with mitigation of peripheral side effects. The company's intellectual property includes acquired assets from NeuroSolis and technology agreements with Stellaromics. Its focus on circuit-specific pharmacotherapies addresses a significant unmet medical need in CNS disorders, potentially offering efficacy and safety advantages. However, as a clinical-stage company, its moat depends on successful clinical development and regulatory approvals, which remain uncertain.

• Clinical Development Risks: The success of MapLight's product candidates depends on timely and successful completion of clinical trials, patient enrollment, and regulatory approvals, which are inherently uncertain and costly.
• Funding and Liquidity Risks: The company has incurred significant losses and will require substantial additional funding to continue operations and advance product candidates. Failure to raise capital on acceptable terms could adversely affect operations.
• Regulatory Risks: Obtaining FDA and other regulatory approvals involves complex processes with no guarantee of success. Delays or denials could impact the company's development timelines and commercialization prospects.
• Operational Risks: Risks include cybersecurity threats, reliance on third-party contractors for clinical trials, and the need to expand infrastructure and personnel to support growth.

• MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, particularly schizophrenia and Alzheimer's disease psychosis (ADP).
• The company was founded by leaders in psychiatry and neuroscience to develop circuit-specific pharmacotherapies targeting neural circuits causally linked to disease.
• Its lead product candidate is ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist (ML-007) co-formulated with a peripherally acting anticholinergic (PAC) designed to activate central muscarinic receptors while mitigating peripheral side effects.
• ML-007C-MA is in Phase 2 clinical trials: the ZEPHYR trial for schizophrenia aims to enroll 300 participants by April 2026 with topline results anticipated in Q3 2026; the VISTA trial for ADP is ongoing with topline results expected in the second half of 2027.
• ML-007 alone or co-formulated with PAC has been evaluated in four Phase 1 trials involving 270 healthy participants and over 1,500 doses administered.
• In December 2025, the FDA granted Fast Track designation to ML-007C-MA for treatment of hallucinations and delusions associated with ADP.
• The company has reported significant net losses since inception, with a net loss of $161.2 million for the year ended December 31, 2025, and an accumulated deficit of $360.5 million as of that date.
• As of December 31, 2025, MapLight had cash, cash equivalents, and investments totaling approximately $453.1 million, including $46.7 million in cash and cash equivalents and $258.4 million in short-term investments, resulting in a strong liquidity position with a current ratio of 20.01 and a cash ratio of 18.8.
• The company completed its initial public offering (IPO) in October 2025, raising net proceeds of $261.6 million, and concurrently closed a private placement raising an additional $7.5 million.
• MapLight leases 13,734 square feet of office and laboratory space in Redwood City, California, under a lease expiring in 2031, and approximately 6,205 square feet of office space in Burlington, Massachusetts, under a lease expiring in 2029 with an option to extend.
• The company has no material legal proceedings as of the latest filing and has not declared or paid dividends, intending to retain funds to support operations and growth.
• Research and development expenses increased significantly in 2025, reflecting clinical trial activities, employee costs, and manufacturing expenses.
• The company has entered into asset purchase and licensing agreements, including acquiring proprietary M1/M4 agonist molecules from NeuroSolis and transferring certain technology rights to Stellaromics, retaining rights to use the technology.
• MapLight's business model relies on advancing clinical trials, obtaining regulatory approvals, and potentially partnering or licensing to commercialize product candidates.
• The company acknowledges risks including the need for substantial additional funding, uncertainties in clinical development timelines and costs, regulatory approval challenges, and operational risks including cybersecurity threats.
• Insider buying activity was reported in February 2026, indicating some insider confidence in the company.
• The company plans multiple Phase 2 readouts in 2026 and has updated the expected timing of topline results for ongoing Phase 2 studies to Q3 2026 for schizophrenia and later for ADP.
• The company’s net loss per share was $18.56 for the year ended December 31, 2025, with a weighted average of approximately 8.68 million common shares outstanding.
• MapLight’s operations are consolidated with its wholly owned Australian subsidiary, and all long-lived assets are held in the United States.
• The company’s board and senior management oversee cybersecurity risk management, with established processes for incident response and reporting to the audit committee.